Skip to main content
SpringerLink
Log in

Vismodegib

  • Chapter
  • First Online:
New Therapies in Advanced Cutaneous Malignancies

  • 353 Accesses

Abstract

Vismodegib is a small molecule inhibitor of smoothened, a key component of the hedgehog (Hh) signaling pathway which is a key regulator of cell growth and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy and metastatic basal cell carcinoma. The efficacy and safety of vismodegib have been shown in phase I and phase II clinical trials and confirmed in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30:303–12.

    Article  CAS  PubMed  Google Scholar 

  3. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:5576–81.

    Article  CAS  PubMed  Google Scholar 

  4. Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026–33.

    Article  CAS  PubMed  Google Scholar 

  5. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc11/2p532/2 mice. Cancer Cell. 2004;6:229–40.

    Article  CAS  PubMed  Google Scholar 

  6. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406–10.

    Article  CAS  PubMed  Google Scholar 

  7. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72.

    Article  Google Scholar 

  8. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Graham RA, Lum BL, Cheet S, et al. Pharmacokinetics of hedgehog pathway Inhibitor vismodegib (GDC- 0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Can Res. 2011;17:2512–20.

    Article  CAS  Google Scholar 

  10. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72:1021.

    Article  PubMed  Google Scholar 

  12. Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48.

    Article  CAS  PubMed  Google Scholar 

  13. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18:404–12.

    Article  PubMed  CAS  Google Scholar 

  14. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36.

    Article  CAS  PubMed  Google Scholar 

  16. Hansson J, Bartley K, Grob JJ, et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. Eur J Dermatol. 2018;28:775–83.

    CAS  PubMed  Google Scholar 

  17. Bossi P, Peris K, Calzavara-Pinton P, et al. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. Future Oncol. 2020;16(16):1091–100.

    Article  CAS  PubMed  Google Scholar 

  18. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.

    Article  CAS  PubMed  Google Scholar 

  19. Lacouture ME, Tang JY, Rogers GS, et al. The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib. J Clin Oncol. 2015;33(15_suppl):9023.

    Google Scholar 

  20. Chang ALS, Lewis KD, Arron TS, et al. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Oncotarget. 2016;7(46):76118–24.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chang AL, Arron ST, Migden MR, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Słowińska M, Maciąg A, Dudzisz-Śledź M, et al. Vismodegib in the treatment of basal cell carcinoma – polish clinical experience in the frame of therapeutic program. Oncol Clin Pract. 2019;15(3):139–49.

    Google Scholar 

  24. Bernia E, Llombart B, Serra-Guillén C, et al. Experience with vismodegib in the treatment of advanced basal cell carcinoma at a cancer center. Actas Dermosifiliogr. 2018;109(9):813–20.

    Article  CAS  PubMed  Google Scholar 

  25. Herms F, Lambert J, Grob JJ, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter french study of 116 patients. J Clin Oncol. 2019;37:3275.

    Article  CAS  PubMed  Google Scholar 

  26. Fife K, Herd R, Lalondrelle S, et al. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol. 2017;13(2):175–84.

    Article  CAS  PubMed  Google Scholar 

  27. Hanke CW, Mhatre SK, Oliveri D, et al. Vismodegib use in clinical practice: analysis of a united states medical claims database. J Drugs Dermatol. 2018;17(2):143–8.

    PubMed  Google Scholar 

  28. Van Eecke L, Vander Borght S, Vanden Bempt I, et al. Vismodegib treatment in patients with advanced basal cell carcinoma: long term efficacy and safety data with focus on secondary resistance and underlying resistance mechanism. Int J Clin Expl Dermatol. 2020;5(1):7–12.

    Google Scholar 

  29. Scalvenzi M, Cappello M, Costa C, et al. Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity. Dermatol Ther (Heidelb). 2020;10(3):465–8.

    Article  Google Scholar 

  30. Chang ALS, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27:342.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389–97.

    Article  CAS  PubMed  Google Scholar 

  33. Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Sternfeld A, Rosenwasser-Weiss S, Ben-Yehuda G. Gene-related response of basal cell carcinoma to biologic treatment with vismodegib. Sci Rep. 2020;10(1):1244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mohan SV, Chang J, Li S, et al. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152:527.

    Article  PubMed  Google Scholar 

  36. Saintes C, Saint-Jean M, Brocard A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib. J Eur Acad Dermatol Venereol. 2015;29(5):1006–9.

    Article  CAS  PubMed  Google Scholar 

  37. Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77:713.

    Article  CAS  PubMed  Google Scholar 

  38. NCCN Guidelines. Basal cell skin cancer. Version 1. 2020.

    Google Scholar 

  39. Kahana A, Worden FP, Elner VM. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131:1364–6.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2013;29:87–92.

    Article  PubMed  Google Scholar 

  41. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high risk basal cell carcinoma. J Am Acad Dermatol. 2014;71:904–11.e1.

    Article  CAS  PubMed  Google Scholar 

  42. Demirci H, Worden F, Nelson CC, et al. Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthalmic Plast Reconstr Surg. 2015;31:463–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73:99–105.e1.

    Article  CAS  PubMed  Google Scholar 

  44. Ching JA, Curtis HL, Braue JA, et al. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma. Ann Plast Surg. 2015;74(suppl 4):S193–7.

    Article  CAS  PubMed  Google Scholar 

  45. Kwon GP, Ally MS, Bailey-Healy I, et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016;75:213–5.

    Article  PubMed  Google Scholar 

  46. Alcalay J, Tauber G, Fenig E, et al. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol. 2015;14:219–23.

    PubMed  Google Scholar 

  47. Mortier L, Bertrand N, Basset-Seguin N et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). J Clin Oncol. 2018; 36(suppl; abstr 9509).

    Google Scholar 

  48. González AR, Etchichury D, Gil ME, Del Aguila R. Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(1):56–61.

    Article  PubMed  Google Scholar 

  49. Sagiv O, Nagarajan P, Ferrarotto R, et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019;103(6):775–80.

    Article  PubMed  Google Scholar 

  50. Su MG, Potts LB, Tsai JH. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib. Am J Ophthalmol Case Rep. 2020;19:100755.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Erivedge (vismodegib), Summary of product characteristics. Last update 10.2020. https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf

  52. Erivedge (vismodegib) capsules, for oral use, prescribing information.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

    Monika Dudzisz-Śledź & Piotr Rutkowski

Authors
  1. Monika Dudzisz-Śledź
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piotr Rutkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Dudzisz-Śledź .

Editor information

Editors and Affiliations

  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

    Piotr Rutkowski

  2. Department of Medicine and Surgery, Unit of Medical OncologyUniversity of Perugia, Perugia, Italy

    Mario Mandalà

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dudzisz-Śledź, M., Rutkowski, P. (2021). Vismodegib. In: Rutkowski, P., Mandalà, M. (eds) New Therapies in Advanced Cutaneous Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-64009-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-64009-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-64008-8

  • Online ISBN: 978-3-030-64009-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation